Bsx with EP slowly healing and litigation fading at under $6 is a steal. Growth, any growth brings tremendous leverage in a terribly difficult environment, Bard, Covidien, even Medtronic could be a suitor. Then Abbott will be forced to step forward with their partner St Judes.
As of right now, Bard has a market cap of $8.26 billion and BSX has a market cap of $8.49 billion. Bard's annual revenue is less than $3 billion, and BSX's annual revenue is around $7.5 billion. You really think a significantly smaller company like Bard is going to buy BSX?
You really think the FTC, SEC, and the EU would allow MDT to buy BSX? No anti-trust concerns with stents and ICDs??!!
You really think the FTC, SEC, and the EU would allow ABT and STJ to buy BSX? No anti-trust concerns with stents and ICDs??!!
BSX didn't grow revenue, if you actually read their revenue report. Why would anybody buy a sinking ship?